BAYER AG

Company Overview

Bayer AG manufactures medicines and other health-related products. It is based in Leverkusen, Germany, and operates in more than 90 countries worldwide. It operates in three main business areas: pharmaceuticals, consumer health, and crop science. It focuses on developing, manufacturing, and selling new medicines, health products, and agricultural solutions. The pharmaceutical division is significant for growth, as it develops treatments for conditions such as heart disease, cancer, blood disorders, and metabolic issues.

In the field of CKD, Bayer operates through its pharmaceuticals division. Its main product for CKD is Kerendia (finerenone), a type of medication that helps people with CKD and type 2 diabetes. The other business areas, such as consumer health and crop science, don't directly address CKD. However, the pharmaceuticals division continues to work on new treatments to slow disease progression and manage related health issues, including heart and kidney problems. It has been expanding its global presence, with a strong focus on Europe, North America, Latin America, and Asia-Pacific.

Financial Highlights (FY 2025)

Company's Business Segments

• Crop Science : Crop protection, seeds and traits, digital farming, fruits & vegetables, environmental science.
• Pharmaceuticals : Treatments and therapies, Cell and gene therapies.
• Consumer Health : Nutritional supplements, Allergy, Cough & cold, Dermatology, Pain and cardiovascular risk prevention, Digestive health.
• All other Segments : The revenue sources here mainly comprise income from marketing rights and from catering services.
• Enabling Functions and Consolidation : Telates to Group-wide competence centers and business support services as well as “Leaps by Bayer"